Vericiguat

Vericiguat, sold under the brand name Verquvo, is a medication used to reduce the risk of cardiovascular death and heart failure.

Vericiguat

Clinical data
Trade names	Verquvo
License data	US DailyMed: Vericiguat
Pregnancy category	Contraindicated
Routes of administration	By mouth
Drug class	Guanylate cyclase activator
ATC code	C01DX22 (WHO)
Legal status
Legal status	US: ℞-only [1]
Identifiers
IUPAC name methyl N-[4,6-diamino-2-[5-fluoro-1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl]carbamate
CAS Number	1350653-20-1
PubChem CID	54674461
DrugBank	DB15456
ChemSpider	32700337
UNII	LV66ADM269
KEGG	D11051
ChEBI	CHEBI:142432
ChEMBL	ChEMBL4066936
ECHA InfoCard	100.247.370
Chemical and physical data
Formula	C19H16F2N8O2
Molar mass	426.388 g·mol^−1
3D model (JSmol)	Interactive image
SMILES COC(=O)NC1=C(N=C(N=C1N)C2=NN(C3=C2C=C(C=N3)F)CC4=CC=CC=C4F)N
InChI InChI=1S/C19H16F2N8O2/c1-31-19(30)25-14-15(22)26-17(27-16(14)23)13-11-6-10(20)7-24-18(11)29(28-13)8-9-4-2-3-5-12(9)21/h2-7H,8H2,1H3,(H,25,30)(H4,22,23,26,27) Key:QZFHIXARHDBPBY-UHFFFAOYSA-N

It was approved for medical use in the United States in January 2021.[2]

References

1. "Prescribing information" (PDF). www.accessdata.fda.gov. Retrieved 20 January 2021.
2. "Verquvo: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 19 January 2021.

Further reading

• Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, et al. (May 2020). "Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction". N Engl J Med. 382 (20): 1883–1893. doi:10.1056/NEJMoa1915928. PMID 32222134.

External links

• "Vericiguat". Drug Information Portal. U.S. National Library of Medicine.